Medical Health Cluster


Anti–SARS-CoV-2 Monoclonal Antibody Distribution to High-risk Medicare Beneficiaries, 2020-2021

Monoclonal antibodies (mAbs) are highly effective in treating mild to moderate COVID-19 among nonhospitalized patients.1 Given limited supply, federal guidelines prioritize patients at higher risk of progression to hospitalization or mortality from COVID-19, with risk factors including age and comorbid conditions.2,3 Antibodies were initially allocated to states by the federal government,4 then distributed […]

Read More

Antibody Quality Improves for Months After COVID-19 Vaccination 

For at least six months after COVID-19 vaccination, antibodies produced by immune cells become steadily more formidable and more precisely targeted against the virus that causes COVID-19, according to a study of the antibody response to the Pfizer-BioNTech vaccine by researchers at Washington University School of Medicine in St. Louis. […]

Read More

Antibody Response and Variant Cross-Neutralization After SARS-CoV-2 Breakthrough Infection

Breakthrough infections after vaccination against SARS-CoV-2 are increasingly reported, possibly due to waning of vaccine-induced antibody levels.1 Moreover, emerging variants of concern with diminished susceptibility to vaccine-induced antibodies are responsible for most new cases.2,3 Studies have focused on determining the rate of vaccine breakthrough based on antibody levels after standard vaccination practices.4,5 We […]

Read More

Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 Years

The durability of response to the SARS-CoV-2 BNT162b2 vaccine (Pfizer-BioNTech) in adults aged 60 years and older has yet to be determined. The immune response to 2 doses of BNT162b2 is lower in individuals aged 65 to 85 years vs 18 to 55 years.1 Among 4868 health care workers receiving 2 […]

Read More

COVID Antibody Treatment Sotrovimab Approved for Use

UK authorisation has been given for sotrovimab for patients with mild to moderate COVID-19 who are at risk of developing severe disease. The Medicines and Healthcare products Regulatory Agency (MHRA) said that the single monoclonal antibody drug was a safe and effective treatment for reducing the risk of hospitalisation and death. Results from a […]

Read More

Reduced Hospital Admission Seen in High-Risk COVID Patients Given Monoclonal Antibody Combo

NEW YORK (Reuters Health) – People with mild to moderate COVID-19 who were treated with casirivimab and imdevimab – two monoclonal antibodies with emergency-use authorization for COVID-19 in the U.S. – had lower hospitalization rates than untreated counterparts in a retrospective study. Dr. Raymund Razonable of Mayo Clinic, in Rochester, […]

Read More